213 related articles for article (PubMed ID: 38341391)
1. Dysregulated hemostasis in acute promyelocytic leukemia.
Hisada Y
Int J Hematol; 2024 May; 119(5):526-531. PubMed ID: 38341391
[TBL] [Abstract][Full Text] [Related]
2. The coagulopathy of acute promyelocytic leukaemia revisited.
Stein E; McMahon B; Kwaan H; Altman JK; Frankfurt O; Tallman MS
Best Pract Res Clin Haematol; 2009 Mar; 22(1):153-63. PubMed ID: 19285282
[TBL] [Abstract][Full Text] [Related]
3. The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Kwaan HC; Cull EH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):11-8. PubMed ID: 24907013
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Zhang X; Zhou H; Wang J; Yang L; Hu Y; Shen G; Guo P; Qiao Z; Song S
Thromb Res; 2002 Apr; 106(1):63-70. PubMed ID: 12165291
[TBL] [Abstract][Full Text] [Related]
5. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Zhao W; Wang H; Wang X; Wu F; Guo W; Qu B; Shen Z; Wang Z
Thromb Res; 2001 May; 102(3):197-204. PubMed ID: 11369412
[TBL] [Abstract][Full Text] [Related]
6. Coagulopathy of acute promyelocytic leukemia.
Falanga A; Barbui T
Acta Haematol; 2001; 106(1-2):43-51. PubMed ID: 11549776
[TBL] [Abstract][Full Text] [Related]
7. Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines.
Olwill SA; McGlynn H; Gilmore WS; Alexander HD
Thromb Res; 2005; 115(1-2):109-14. PubMed ID: 15567461
[TBL] [Abstract][Full Text] [Related]
8. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Liu Y; Wang Z; Jiang M; Dai L; Zhang W; Wu D; Ruan C
Leuk Res; 2011 Jul; 35(7):879-84. PubMed ID: 21146216
[TBL] [Abstract][Full Text] [Related]
9. The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia.
Kwaan HC; Weiss I; Tallman MS
Semin Thromb Hemost; 2019 Sep; 45(6):612-621. PubMed ID: 31370070
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
Wang P; Zhang Y; Yang H; Hou W; Jin B; Hou J; Li H; Zhao H; Zhou J
Hematology; 2018 Dec; 23(10):756-764. PubMed ID: 29724147
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
Lavallée VP; Chagraoui J; MacRae T; Marquis M; Bonnefoy A; Krosl J; Lemieux S; Marinier A; Pabst C; Rivard GÉ; Hébert J; Sauvageau G
Leukemia; 2018 Jun; 32(6):1349-1357. PubMed ID: 29550835
[TBL] [Abstract][Full Text] [Related]
12. The unique hemostatic dysfunction in acute promyelocytic leukemia.
Kwaan HC
Semin Thromb Hemost; 2014 Apr; 40(3):332-6. PubMed ID: 24590422
[TBL] [Abstract][Full Text] [Related]
13. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.
Kwaan HC; Rego EM
Semin Thromb Hemost; 2010 Nov; 36(8):917-24. PubMed ID: 21049391
[TBL] [Abstract][Full Text] [Related]
14. Annexin II and bleeding in acute promyelocytic leukemia.
Menell JS; Cesarman GM; Jacovina AT; McLaughlin MA; Lev EA; Hajjar KA
N Engl J Med; 1999 Apr; 340(13):994-1004. PubMed ID: 10099141
[TBL] [Abstract][Full Text] [Related]
15. Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia.
Jácomo RH; Santana-Lemos BA; Lima AS; Assis PA; Lange AP; Figueiredo-Pontes LL; Oliveira LO; Bassi SC; Benício MT; Baggio MS; Garcia AB; Falcão RP; Rego EM
Blood; 2012 Jul; 120(1):207-13. PubMed ID: 22517898
[TBL] [Abstract][Full Text] [Related]
16. Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia.
Li S; Gao Y; Li F; Zheng Y; Su Y
Ann Hematol; 2023 Apr; 102(4):787-794. PubMed ID: 36750485
[TBL] [Abstract][Full Text] [Related]
17. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.
Chang H; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Tang TC
Eur J Haematol; 2012 Apr; 88(4):321-8. PubMed ID: 22221178
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia.
Xiao M; Zhou P; Liu Y; Wei S; Li D; Li W; Niu X; Niu J; Zhang Y; Cao W; Liu B; Wang X; Bai Y; Sun K
Thromb Res; 2022 Feb; 210():33-41. PubMed ID: 34998209
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of coagulopathy in acute promyelocytic leukemia.
Sanz MA; Montesinos P
Thromb Res; 2020 Jul; 191 Suppl 1():S63-S67. PubMed ID: 32736781
[TBL] [Abstract][Full Text] [Related]
20. Predictors of early hemorrhage in acute promyelocytic leukemia.
Naymagon L; Moshier E; Tremblay D; Mascarenhas J
Leuk Lymphoma; 2019 Oct; 60(10):2394-2403. PubMed ID: 30849255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
